Integrin Regulation of C-Abl Tyrosine Kinase Activity and Cytoplasmic-nuclear Transport
Overview
Affiliations
The product of the c-abl protooncogene is a nonreceptor tyrosine kinase found in both the cytoplasm and the nucleus. We report herein that cell adhesion regulates the kinase activity and subcellular localization of c-Abl. When fibroblastic cells are detached from the extracellular matrix, kinase activity of both cytoplasmic and nuclear c-Abl decreases, but there is no detectable alteration in the subcellular distribution. Upon adhesion to the extracellular matrix protein fibronectin, a transient recruitment of a subset of c-Abl to early focal contacts is observed coincident with the export of c-Abl from the nucleus to the cytoplasm. The cytoplasmic pool of c-Abl is reactivated within 5 min of adhesion, but the nuclear c-Abl is reactivated after 30 min, correlating closely with its return to the nucleus and suggesting that the active nuclear c-Abl originates in the cytoplasm. In quiescent cells where nuclear c-Abl activity is low, the cytoplasmic c-Abl is similarly regulated by adhesion but the nuclear c-Abl is not activated upon cell attachment. These results show that c-Abl activation requires cell adhesion and that this tyrosine kinase can transmit integrin signals to the nucleus where it may function to integrate adhesion and cell cycle signals.
Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma.
Zhang Y, Ojalill M, Boyer A, Chen X, Tahon E, Thivolle Lioux G Cancer Res Commun. 2024; 4(12):3165-3179.
PMID: 39585085 PMC: 11659947. DOI: 10.1158/2767-9764.CRC-24-0382.
Myristoyl's dual role in allosterically regulating and localizing Abl kinase.
de Buhr S, Grater F Elife. 2023; 12.
PMID: 37843155 PMC: 10619977. DOI: 10.7554/eLife.85216.
Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance.
Rudich A, Garzon R, Dorrance A Int J Mol Sci. 2022; 23(20).
PMID: 36293127 PMC: 9603161. DOI: 10.3390/ijms232012271.
Luttman J, Colemon A, Mayro B, Pendergast A Cell Commun Signal. 2021; 19(1):59.
PMID: 34022881 PMC: 8140471. DOI: 10.1186/s12964-021-00739-6.
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
Osman A, Deininger M Blood Rev. 2021; 49:100825.
PMID: 33773846 PMC: 8563059. DOI: 10.1016/j.blre.2021.100825.